Pasar al contenido principal

ENTENDIENDO LA INTERACCION ENTRE NANOCAPSULAS Y EL SURFACTANTE PULMONAR PARA LA MEJORA DE SU EFECTO TERAPEUTICO

PID2019-106139RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ultrasmall manganese ferrites for in vivo catalase mimicking activity and multimodal bioimaging

  • Carregal-Romero, Susana
  • Miguel-Coello, Ana Beatriz
  • Martínez-Parra, Lydia
  • Martí-Mateo, Yolanda
  • Hernansanz-Agustín, Pablo
  • Fernández-Afonso, Yilian
  • Plaza-García, Sandra
  • Gutiérrez, Lucía
  • Muñoz-Hernández, María del Mar
  • Carrillo-Romero, Juliana
  • Piñol-Cancer, Marina
  • Lecante, Pierre
  • Blasco-Iturri, Zuriñe
  • Fadón, Lucía
  • Almansa-García, Ana C.
  • Möller, Marco
  • Otaegui, Dorleta
  • Enríquez, Jose Antonio
  • Groult, Hugo
  • Ruíz-Cabello, Jesús
Manganese ferrite nanoparticles display interesting features in bioimaging and catalytic therapies. They have been recently used in theranostics as contrast agents in magnetic resonance imaging (MRI), and as catalase-mimicking nanozymes for hypoxia alleviation. These promising applications encourage the development of novel synthetic procedures to enhance the bioimaging and catalytic properties of these nanomaterials simultaneously. Herein, a cost-efficient synthetic microwave method is developed to manufacture ultrasmall manganese ferrite nanoparticles as advanced multimodal contrast agents in MRI and positron emission tomography (PET), and improved nanozymes. Such a synthetic method allows doping ferrites with Mn in a wide stoichiometric range (MnxFe3-xO4, 0.1 ≤ x ≤ 2.4), affording a library of nanoparticles with different magnetic relaxivities and catalytic properties. These tuned magnetic properties give rise to either positive or dual-mode MRI contrast agents. On the other hand, higher levels of Mn doping enhance the catalytic efficiency of the resulting nanozymes. Finally, through their intracellular catalase-mimicking activity, these ultrasmall manganese ferrite nanoparticles induce an unprecedented tumor growth inhibition in a breast cancer murine model. All of these results show the robust characteristics of these nanoparticles for nanobiotechnological applications., The authors thank M. Jeannin from Lasie Laboratory (La Rochelle University) for the Raman studies. S.C.R. is supported by the grant PID2019-106139RA-100 funded by MCIN. J.R.-C. is supported by grants from the Ministerio de Economía, Industria y Competitividad (MEIC) (SAF2017-84494-C2-R). J.R.C. received funding from the BBVA Foundation (PR [18]_BIO_IMG_0008) and La Caixa (HR18-00052). Y.F.-A. received funding from the Santander-Universidad Zaragoza Fellowship program. L.G. acknowledges financial support from the Ramón y Cajal program (RYC-2014-15512). CIC biomaGUNE is supported by the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (MDM-2017-0720). The authors acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza. H.G. is supported by the Ligue contre le Cancer (CD16, CD17) and Région Nouvelle Aquitaine (Projet “Nanovect”). J.A.E. is supported by RTI2018-099357-B-I00, HFSP (RGP0016/2018), CIBERFES16/10/00282 and RED2018-102576-T. The CNIC is supported by the Pro-CNIC Foundation and by the Severo Ochoa of Excellence Program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Comparative Study of Ultrasmall Calcium Carbonate Nanoparticles for Targeting and Imaging Atherosclerotic Plaque

  • Martínez-Parra, Lydia
  • Piñol-Cancer, Marina
  • Sanchez-Cano, Carlos
  • Miguel-Coello, Ana Beatriz
  • Di Silvio, Desiré
  • Gómez, Ana M.
  • Uriel, Clara
  • Plaza-García, S.
  • Gallego, M.
  • Pazos, Raquel
  • Groult, Hugo
  • Jeannin, Marc
  • Geraki, Kalotina
  • Fernández-Méndez, Laura
  • Urkola-Arsuaga, Ainhize
  • Sánchez-Guisado, Mª Jesús
  • Carrillo-Romero, Juliana
  • Parak, Wolfgang J.
  • Prato, Maurizio
  • Herranz, Fernando
  • Ruíz-Cabello, Jesús
  • Carregal-Romero, Susana
therosclerosis is a complex disease that can lead to life-threatening events, such as myocardial infarction and ischemic stroke. Despite the severity of this disease, diagnosing plaque vulnerability remains challenging due to the lack of effective diagnostic tools. Conventional diagnostic protocols lack specificity and fail to predict the type of atherosclerotic lesion and the risk of plaque rupture. To address this issue, technologies are emerging, such as noninvasive medical imaging of atherosclerotic plaque with customized nanotechnological solutions. Modulating the biological interactions and contrast of nanoparticles in various imaging techniques, including magnetic resonance imaging, is possible through the careful design of their physicochemical properties. However, few examples of comparative studies between nanoparticles targeting different hallmarks of atherosclerosis exist to provide information about the plaque development stage. Our work demonstrates that Gd (III)-doped amorphous calcium carbonate nanoparticles are an effective tool for these comparative studies due to their high magnetic resonance contrast and physicochemical properties. In an animal model of atherosclerosis, we compare the imaging performance of three types of nanoparticles: bare amorphous calcium carbonate and those functionalized with the ligands alendronate (for micro- calcification targeting) and trimannose (for inflammation targeting). Our study provides useful insights into ligand-mediated targeted imaging of atherosclerosis through a combination of in vivo imaging, ex vivo tissue analysis, and in vitro targeting experiments., We acknowledge M. Spuch for his scientific drawings and the Basque Government for the R&D Project in Health (grant number 2022333041). S.C.R. acknowledges the Spanish Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI) Grant PID2019-106139RA-100 funded by MCIN/AEI/10.13039/501100011033 and the Ramon y Cajal Grant RYC2020-030241-I. C.S.C. acknowledges financial support from the Spanish State Research Agency (grant PID2020-118176RJ-I100), and the Gipuzkoa Foru Aldundia (Gipuzkoa Fellows program; grant number 2019-FELL- 000018-01/62/2019). This work was performed under the Severo Ochoa Centers of Excellence Program of the Spanish State Research Agency − Grant No. CEX2018-000867-S (DIPC). SXRF analysis was carried out with the support of Diamond Light Source, beamline I18 (proposal SP27720). J.R.C. is funded by MCIN/AEI/10.13039/501100011033 (PID2021-123238OB-I00) and from La Caixa Foundation (Health Research Call 2020: HR20-00075). A.M.G. and C.U. acknowledge the Spanish Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI) Grant: PID2021-122504NB-I00 funded by MCIN/AEI/10.13039/ 501100011033 and by “ERDF A way of making Europe. W.J.P. acknowledges funding from the Cluster of Excellence “Advanced Imaging of Matter” of the Deutsche Forschungsge- meinschaft (DFG) - EXC 2056 - project ID 390715994. F.H. acknowledges MCIN (PID2019-104059RB-I00) and M.J.S.G. the Spanish Ministerio de Educación y Formación Profesional (PRE2018-083691)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NIR-II Photoresponsive magnetoliposomes for remote-controlled release and magnetic resonance imaging

  • Fernández-Méndez, Laura
  • Fernández-Afonso, Yilian
  • Martínez-Vicente, Pablo
  • Urkola-Arsuaga, Ainhize
  • Miranda-Pérez de Alejo, Claudia
  • Pisa, Irati L. de la
  • Plaza-García, Sandra
  • Ruíz-Cabello, Jesús
  • Ramos-Cabrer, Pedro
  • Gutiérrez, Lucía
  • Carregal-Romero, Susana
Magnetic nanoparticles, especially iron oxide nanoparticles, have become versatile and widely used tools in nanomedicine due to their unique magnetic properties, biocompatibility, and tunable functionality. Liposomes have further enhanced the potential of iron oxide nanoparticles by serving as effective nanocarriers with advantages such as drug coencapsulation and enhanced molecular imaging properties. In this study, we present magnetoliposomes composed of ultrasmall free-floating iron oxide nanoparticles inside liposomes (LP-IONPs) and thermoresponsive phospholipids, which were designed as dual T2-T1 magnetic resonance imaging (MRI) contrast agents for image-guided liposome degradation and infrared light-responsive nanocarriers in the second biological window for remote-controlled drug delivery. We demonstrated a dynamic shift from T2 to T1 MRI contrast during intracellular degradation of LP-IONPs, along with successful light-activated drug release in cancer cells. Biodistribution studies using MRI and histological analysis confirmed their potential for in vivo applications. These results highlight the potential of LP-IONPs as image-guided and remote-controlled drug delivery systems., S.C.R. thanks the MCIN/AEI 10.13039/501100011033 projects (PID2019-106139RA-100, CNS2023-143944, RYC2020-030241-I, and PID2022-142842OB-I00), the Ikerbasque (Basque Foundation for Science), and the Ramón Areces Foundation (CIVP21S13151). J.R.C. is funded by MCIN/AEI/10.13039/501100011033 (PID2021-123238OB-I00), the Basque Government through the Elkartek 2024 program (bmG24), and R&D projects in Health (grant number 2022333041). S.C.R. and J.R.C. thank IKERBASQUE for its support. L.G. thanks Project CNS2023-144321, funded by MICIU/AEI/10.13039/501100011033 and NextGenerationEU/PRT, and Fondo Social del Gobierno de Aragón (grupo DGA E15-23R). We also thank the Fundación contra la Hipertensión Pulmonar for funding (Empathy). CIBERES and CIBERBBN were co-funded by FEDER and ISCIII., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The role of PEGylation in the pulmonary delivery of antifibrotic liposomal therapies

  • Piñol Cancer, Marina
  • Fernández Méndez, Laura
  • Carrillo Romero, Juliana
  • Urkola Arsuaga, Ainhize
  • Azkargorta, Mikel
  • Elortza, Félix
  • Goñi de Cerio, Felipe
  • García Mouton, Cristina
  • Miranda-Pérez de Alejo, Claudia
  • Ismalaj, Ermal
  • Cañadas Benito, Olga
  • Pérez Gil, Jesús
  • Ruiz-Cabello Osuna, Jesús
  • Carregal Romero, Susana
PEGylation is commonly used to improve the pharmacokinetics and efficacy of intravenously administered drug nanocarriers; however its impact on pulmonary drug delivery remains unclear. While previous studies have focused on its role in crossing the lung mucosal barrier and stabilizing formulations for nebulization, less is known about its effects on lung surfactant corona composition, biodistribution, and therapeutic efficacy. Here, we present a multiscale study on how PEG-free and PEGylated liposomes loaded with pirfenidone interact with pulmonary barriers. PEGylation increased mucus penetration and reduced protein adsorption in the lung surfactant corona. However, statistical analysis of functional proteins showed only moderate changes in anti-inflammatory and adhesion proteins, with no apparent effect on key surfactant proteins that influence liposome fate in the lung. This correlated with similar biodistributions and retention times in both healthy and fibrotic lungs for PEG-free and PEGylated liposomes. Concerningly, PEGylated liposomes enhanced native surfactant fluidity, potentially altering lung function. In a bleomycin-induced pulmonary fibrosis model, both PEG-free and PEGylated liposomes improved the antifibrotic efficacy of pirfenidone. However, PEGylation attenuated the reduction in fibrotic biomarkers within the lung fluid. These findings suggest that, although PEGylation facilitates mucus penetration, it does not significantly enhance therapeutic outcomes and may adversely affect lung function. This study provides critical insights into the optimization of lipid-based nanocarriers for pulmonary fibrosis and other lung diseases.